Table 3 Factors influencing appropriateness or not of EAMT

Age, years (mean ± SD)

50 ± 18

55 ± 16

0.18

Age > 50 years, n (%)

22 (53%)

26 (68%)

0.2

2.4

[0.67–8.51]

0.17

Sex-ratio

26/15

21/17

0.49

SAPS II

36 ± 14

40 ± 16

0.26

SOFA

5.2 ± 2.9

6.5 ± 3.7

0.076

SOFA > 5, n (%)

14 (34%)

20 (52%)

0.13

1.66

[0.54–5.06]

0.36

Origin of NI acquisition

 Medical ICU

9 (22%)

14 (37%)

0.18

0.61

[0.10–3.64]

0.6

 ED*

22 (53%)

15 (39%)

0.20

1.14

[0.30–4.33]

0.84

 Medical department

5 (12%)

8 (21%)

0.32

 Other

5 (12%)

1 (2.6)

–

Co-morbidities

 Diabetes

17 (41%)

14 (37%)

0.36

0.26

[0.075–0.93]

0.038

 Chronic respiratory failure

19 (46%)

8 (21%)

0.032

1.42

[0.43–4.67]

0.56

 Immunosuppression/neoplasia

7 (17%)

6 (16%)

0.99

 Cardiovascular disease

17 (41%)

24 (63%)

0.079

Nature of suspected NI:

 VAP

33 (80%)

26 (68%)

0.2

0.6

[0.19–1.94]

0.40

 Bloodstream infection

6 (15%)

6 (16%)

–

 CRI

2 (5%)

5 (13%)

–

 UI

0

1 (2.6%)

–

LOS pre-NI acquisition, days (med [IQR])

5 [3–10]

8 [6–14]

0.09

LOS pre-NI > 6 days

10 (24%)

20 (52%)

0.012

4.44

[1.06–20.4]

0.05

Prior antimicrobials

32 (78%)

32 (84%)

0.57

Pre-exposure to imipenem

10 (24%)

11 (29%)

0.8

Pre-exposure to beta-lactams (other than imipenem)

20 (49%)

18 (47%)

0.82

Pre-exposure to colistin

7 (17%)

8 (21%)

0.77

Pre-exposure to glycopeptides

7 (17%)

4 (10.5%)

0.52

Recent surgery

4 (10%)

10 (26.5%)

0.061

1.69

[0.37–7.66]

0.49

Shock

16 (39%)

16 (42%)

0.82

Mechanical ventilation

40 (97.5%)

37 (97.3%)

1

Tracheostomy

17 (41%)

16 (42%)

0.81

Current corticosteroid

5 (12%)

5 (13%)

1